Dr. Britt is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4715 Arapahoe Avenue
Boulder, CO 80303Phone+1 303-385-2000
Summary
- Dr. Gregory Britt is a practicing board-certified hematologist and medical oncologist at Rocky Mountain Cancer Center in Boulder, CO. Previously, he was medical director of the Cancer Centers of Colorado in Denver, CO, where he also served as Section Chief of Hematology and Medical Oncology at Saint Joseph Hospital, Denver.
His background and interests include: pharmaceutical clinical trials, healthcare quality, external peer review, and medicolegal consulting.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Tufts Medical CenterResidency, Internal Medicine, 2004 - 2007
Georgetown University School of MedicineClass of 2004
Certifications & Licensure
CO State Medical License 2013 - 2025
MA State Medical License 2006 - 2017- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012
Publications & Presentations
PubMed
- 147 citationsThe Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR MutationsStephanie Heon, Beow Y. Yeap, Neal I. Lindeman, Victoria A. Joshi, Mohit Butaney
Clinical Cancer Research. 2012-06-25 - 179 citationsDevelopment of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.Stephanie Heon, Beow Y. Yeap, Gregory J. Britt, Daniel B. Costa, Michael S. Rabin
Clinical Cancer Research. 2010-12-01 - 2 citationsTreatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes.Leah Wells, Michael Cerniglia, Sarah Hall, Audrey C Jost, Gregory Britt
Journal of Immunotherapy and Precision Oncology. 2022-05-01
Professional Memberships
- Member
Industry Relationships
- Parexel International, CROClinical Data Associate/Manager. Serious adverse event lead for global phase III trials.1998 - 2000
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
